drugset / Trial / NCT00338936
Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydrochlorothiazide | Unknown | 6.25 mg | — |
| Subject | Hydrochlorothiazide | Unknown | 12.5 mg | — |
| Subject | Valsartan | Small molecule | 40 mg | — |
| Subject | Valsartan | Small molecule | 80 mg | — |